Compare STAG & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAG | KRYS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 7.8B |
| IPO Year | 2010 | 2017 |
| Metric | STAG | KRYS |
|---|---|---|
| Price | $38.60 | $270.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $39.20 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 1.2M | 220.6K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 6.84 |
| Revenue | ★ $845,184,000.00 | $389,130,000.00 |
| Revenue This Year | $8.59 | $39.88 |
| Revenue Next Year | $9.28 | $34.38 |
| P/E Ratio | ★ N/A | $39.08 |
| Revenue Growth | 10.14 | ★ 33.94 |
| 52 Week Low | $31.64 | $123.03 |
| 52 Week High | $39.98 | $298.30 |
| Indicator | STAG | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 59.98 |
| Support Level | $36.80 | $255.65 |
| Resistance Level | $39.51 | $297.14 |
| Average True Range (ATR) | 0.65 | 8.92 |
| MACD | 0.28 | 2.06 |
| Stochastic Oscillator | 95.35 | 85.16 |
Stag Industrial Inc is a REIT focused on the acquisition, ownership, development, and operation of industrial properties throughout the United States. Its platform is designed to (i) identify properties for acquisition that offer attractive returns across CBRE-EA Tier 1 industrial real estate markets, industries, and tenants, (ii) provide growth through the ownership of high-quality assets, property management and pursuit of acquisitions in an attractive opportunity set, and (iii) capitalize its business appropriately given the characteristics of its assets. The majority of its portfolio is single-tenant industrial properties throughout the United States. The company derives the majority of its rental revenue from its facilities located in Midwestern and Eastern U.S. cities.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.